VEGF INHIBITOR DRUGS IN THE TREATMENT OF DIABETIC RETINOPATHY: A REVIEW
Keywords:
anti-VEGF drugs, diabetic retinopathy, diabetic macular edemaAbstract
Relevance: For the treatment of diabetic retinopathy (DRP) in the setting of diabetic macular edema (DME), the development of which is associated with the influence of vascular endothelial growth factor (VEGF), agents with anti-VEGF activity are used. The article provides an analytical review of these agents. Objective: to evaluate the comparative capabilities of anti-VEGF agents in the treatment of DRP. Material and methods: Eleven sources of literature on the above topic, identified using the PubMed search engine, were analyzed. Results: a comparative analysis of existing agents with anti-VEGF activity and used for intravitreal administration during DRP in DME conditions (bevacizumab, ranibizumab, aflibercept, brolucizumab) was carried out. Conclusion: Understanding the pathogenesis and molecular mechanisms underlying the development of DRP plays an important role in the development of innovative treatments for this condition. Research aimed at finding new therapeutic targets for DRP in the setting of DME may open up new opportunities to more effectively combat this complication of diabetes and prevent blindness and low vision.
References
1. Baker K.V., Glassman A.R., Boley V.T., DRCR Retina Network et al. The effect of initial treatment with aflibercept versus laser photocoagulation and observation on vision loss in patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019; 321(19): 1880–1894.
2. Garweg J.G. A randomized double-masked phase III multicenter study to evaluate the efficacy and safety of brolucizumab compared to aflibercept in patients with vision impairment due to diabetic macular edema (KITE). Klin Monbl Augenheilkd. 2020; 237(4): 450–453.
3. Lang G.E., Liakopoulos S., Fögeler J. et al. RELATION Study: Efficacy and safety of ranibizumab in combination with laser photocoagulation compared to laser monotherapy in patients with NPDR and PDR with diabetic macular edema. Acta Ophthalmol. 2018; 96(3): e377–e385.
4. Ferrara N., Damico L., Shams N. et al. Development of ranibizumab, an anti-VEGF antigen-binding fragment for the treatment of neovascular age-related macular degeneration. Retina. 2006; 26(8): 859–870. Low J., Araujo J., Yan J. et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007; 85(4): 425–430.
5. Fechter S., Fraser H., Marcus W.B. et al. Ranibizumab 0.3 mg for persistent diabetic macular edema after recent, frequent, and chronic bevacizumab: the ROTATE study. Ophthalmic Surg Lasers Imaging Retina. 2016; 47(11): 1–18.
6. Mansur A.M., Al-Ghadban S.I., Younis M.H. et al. Ziv-aflibercept in macular disease. Br J Ophthalmol. 2015; 99(8): 1055–1059.
7. Maturi R.K., Glassman A.R., Yosik K., DRCR Retina Network et al. Effect of intravitreal anti-vascular endothelial growth factor compared with sham treatment for the prevention of vision-threatening complications of diabetic retinopathy: Protocol W of a randomized clinical trial. JAMA Ophthalmol. 2021; 139(7): 701–712.
8. Michaelides M., Keynes A., Hamilton R.D. et al. Prospective randomized study of intravitreal bevacizumab versus laser therapy for diabetic macular edema (BOLT study). Twelve-month data: report 2. Ophthalmology. 2010; 117(6): 1078–1086.e2.
9. Cheng Y.D., Yan H., Chen G.K. et al. Molecularly targeted drugs for the treatment of metastatic colorectal cancer. Drug Des Devel Ther. 2013; 7: 1315–1322.
10. Yuldasheva N.M., Tadjieva F.S., Yuldasheva M. M. Diabetic Vitreopathy in Patients with Type 1 Diabetes Mellitus, Relationship with Local and Systemic Factors - «Teikyo Medical Journal», ISSN: 03875547 Volume 45, Issue 01, February, 2022.
11. Yuldasheva N.M., Tadjiyeva F.S., Ilyasov Sh.Sh., Ishanxadjaeva F.Sh., Yuldashev Sh.M- Усиления тракции при антиVEGF- терапии диабетической макулопатии (случай из практики). «XXI asr qand kasalligi. Global muammolar, local yechim» ilmiy-amaliy konferensiyaga bag’ishlangan Toshkent tibbiyot akademiyasi axborotnomasining maxsus soni. 2019 - yil. 123-125 б. ISSN 2181-7812. O’zbekiston. Toshkent
12. Yuldasheva N.M., Tadjieva F.S Ранняя оценка стекловидного тела у молодых людей при сахарном диабете 1 типа. Russian ophthalmological journal. 2022; 15(3): 80-84
13. Yuldasheva N.M., Tadjieva F.S., Sultanova F. A Оценка состояния стекловидного тела у условно здоровых лиц по данным МСКТ. Новый день в медицине. 2023; 3 (53); С. 225-229
14. Yuldasheva N.M., Tadjieva F.S., Sultanova F. A. Роль стекловидного тела в развитии и прогрессировании диабетической ретинопатии. Специальный выпуск журнала “Инфекция, иммунитет и фармакология” посвящённый международной научно-практической конференция «Проблемы и этапы развития иммунофизиологии в новом Узбекистане». Узбекистан, Ташкент 2023; C. 173-180
15. Wykoff CC, Le RT, Khurana RN, исследовательская группа ENDURANCE и др. Результаты применения афлиберцепта и макулярного лазера по мере необходимости после III фазы исследования VISTA DME: 12-месячное продленное исследование ENDURANCE. Am J Офтальмол. 2017 год; 173 :56–63.
